Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
试验速览
- 阶段
- 不适用
- 入组人数
- 2,000
- 试验地点
- 1
- 主要终点
- To investigate the prevalence of MAFLD among adults at multiple health examination centers across China.
研究概览
简要总结
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
详细描述
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged between 18 and 75, both sex;
- •Able to sign informed consent.
排除标准
- •Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.
结局指标
主要结局
To investigate the prevalence of MAFLD among adults at multiple health examination centers across China.
时间窗: through study completion, an average of 1 year
MAFLD means metabolic dysfunction-associated fatty liver disease
次要结局
- To assess the prevalence of type 2 diabetes among patients with MAFLD.(through study completion, an average of 1 year)
- To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²)(through study completion, an average of 1 year)
- To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²).(through study completion, an average of 1 year)
- To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD.(through study completion, an average of 1 year)